Skip to content

QPHARMA

Active Private limited companyfounded 2023active for 3 yearsXavier De Buestraat 27, 1180 UccleKBO/BCE: BE 0799.745.895

Lifetime

3 annual accounts with figures on one time axis
peak of €80,642 in 2023
€79,141▲ 14.7%
peak of €58,793 in 2023
€53,114▲ 13.4%
peak of €108,139 in 2024
€2,500▼ 97.7%
€182,104▲ 726%
Board1 name since 2023
1 director
Documentsfilings and deeds
06-07-202625 days before the deadline
2025micro format
Gross margin from €68,985 to €79,141Dividend €158,753Equity from €108,139 to €2,500Debts from €22,059 to €182,104

Key points

from the 2025 annual accounts

Equity

€2,500 ▼ 97.7%
€108,0002024€2,5002025

Equity fell in 2025 from €108,139 to €2,500.

Turnover

≈ €160,000 estimated

The micro format states no turnover.

Debts

€182,104 99% of the balance sheet
Suppliers 0%Taxes and wages 13%Other 87%

Liquidity

0.88 was 4.50 in 2024

Short-term debts rose from €22,059 to €182,104.

Filings

3 annual accounts 2 late
AprilJune31 JulyOctober202320242025

The 2023 accounts came in latest, 63 days after the end of the period.

Position in the sector

1.4%

Lower solvency than 90% of companies in head offices and management consultancy. Sector median 55.5% · 41,246 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,156 companies had the same profile as QPHARMA has now. Each dot stands for 6 companies, two years later.

94.1%
were still trading
2.8%
stopped another way
3.0%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,156 companies, not a prediction for QPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 23-03-2023
Board & ownership

Recent changes

Registered office moved within Uccle The registered office moved from Avenue Brugmann 383 bte 2 à 1180 Uccle to Rue Xavier de Bue n° 27 bte 9 à 1180 Uccle · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0799745895
Registered office moved from Woluwe-Saint-Lambert to Uccle The registered office moved from Avenue du Roi Chevalier 13, 1200 Woluwé-Saint-Lambert to Avenue Brugmann 383, boite 2, 1180 Uccle · General meeting of 01-12-2023 · Gazette deed
Incorporation Founding capital of €2,500, 100 shares · Founder: · Appointment: (director) · published on 23-03-2023 · Gazette deed
All 10 events

Comparable companies

same main activity, similar in size and age
Company
QPHARMA Uccle €184,604 €79,141 1.4% -
BLR MANAGEMENT Uccle €195,437 €78,021 32.8% -
Digixperts 360 Uccle €208,805 €84,911 60.3% -
AD Vitam Corp Uccle €174,187 €68,827 49.5% -
So-EU Watermael-Boitsfort €191,576 €77,874 79.8% -
AGMAX CONSULTING Etterbeek €199,083 €81,750 74.6% -
JIL Consult Auderghem €201,338 €83,871 81.0% -

These companies have the same main activity as QPHARMA: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €174,000 and €209,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 21-03-2023Normal situation
Activity
Business and other management consultancyNACE 70200and 1 other
Establishment unit
2.343.292.7421200 Woluwe-Saint-Lambert, since 21-03-2023
Financial year end
31 December
Peppol
Reachable since 15-12-2025
Company details

Annual accounts 2025

€184,604▲ 41.8%
Filing
Filed on 06-07-2026, 25 days before the end of the filing period
Financials

Insights on QPHARMA

QPHARMA files the micro format. That format states no turnover. The gross margin fell from €80,642 in 2023 to €79,141 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about QPHARMA

What is the company number of QPHARMA?
The company number of QPHARMA is 0799.745.895. The VAT number is the same number with BE in front: BE 0799.745.895.
Where is QPHARMA based?
The registered office is at Xavier De Buestraat 27, 1180 Uccle.Company details
What does QPHARMA do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of QPHARMA?
QPHARMA is a private limited company (BV).
When was QPHARMA founded?
QPHARMA was founded on 21-03-2023.
Is QPHARMA still active?
Yes, QPHARMA is an active enterprise in the KBO register.
What is the turnover of QPHARMA?
The turnover in financial year 2025 is ≈ €160,000. This figure is estimated from the gross margin of €79,141 and 138 comparable companies (NACE 70200). It probably lies between €120,000 and €210,000.Financials
Is QPHARMA profitable?
In financial year 2025, QPHARMA made a profit of €53,114.
Where can I find the annual accounts of QPHARMA?
QPHARMA filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of QPHARMA due?
QPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.